Table 3.
SARS-CoV-2-Derived Non-RBD-Binding Antibodies
| mAb name and source | Neutralizing activity | Region targeted in S protein | Receptor and mAb competition | Neutralizing mechanism | Protective efficacy |
PDB/Refs |
|---|---|---|---|---|---|---|
| 2-17, 5-24, and 4-8 Human mAbs |
Neutralize authentic SARS-2 and pseudoviruses | SARS-2 NTD | mAbs compete | Unknown | N/A | [31] |
| COV57 Human pAb |
Neutralizes authentic SARS-2 and pseudoviruses | SARS-1 and SARS-2 NTD, MERS S glycoprotein | Might not interrupt hACE-2 binding | Unknown | Promising candidate against SARS-2 infections | [28,30,37,38,73] |
| 9A1 | Does not neutralize authentic SARS-2 virus | SARS-2 S2 domain | May not interrupt hACE-2 Binding | N/A | 2M-10B11 protects against pseudotyped virus 9A1 confers weak protection |
N/A [38,88] |
| 4A8, 1M-1D2, and 0304-3H3 Human mAbs |
4A8 neutralizes both authentic and pseudotyped SARS-2 1M-1D2 and 0304-3H3 neutralize only authentic SARS-2 virus |
4A8: NTD of S1 1M-1D2: S1 domain 0304-3H3: S2 domain |
Do not interrupt hACE-2 binding 4A8 competes with 1M-1D2 |
Likely by restraining conformational change in S protein | Preclinical | 4A8: 7C2L [88] |
| CV1 and CV35 Human mAbs |
Neutralize SARS-2 | Outside the RBD | N/A | Unknown | N/A | N/A [80] |